List of Lumakras drug patents

Lumakras is owned by Amgen Inc.

Lumakras contains Sotorasib.

Lumakras has a total of 3 drug patents out of which 0 drug patents have expired.

Lumakras was authorised for market use on 28 May, 2021.

Lumakras is available in tablet;oral dosage forms.

Lumakras can be used as treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy.

Drug patent challenges can be filed against Lumakras from May, 2025.

The generics of Lumakras are possible to be released after 11 August, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10519146 AMGEN INC KRAS G12C inhibitors and methods of using the same
May, 2038

(15 years from now)

US11236091 AMGEN INC Solid state forms
May, 2040

(17 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426404 AMGEN INC Dosing of KRAS inhibitor for treatment of cancers
Aug, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026
Orphan Drug Exclusivity (ODE) May 28, 2028

Drugs and Companies using SOTORASIB ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in